BRAF and melanoma: Moreover, while the expression of these melanoma differentiation antigens was back to basal level in patients on progression, in a patient who then was treated with a BRAF/MEK inhibitor combination, the MITF target genes were again upregulated in response to treatment (Frederick et al., 2013).